Sibeprenlimab Demonstrates Kidney Function Preservation in IgA Nephropathy: Insights from the Final Phase 3 VISIONARY Trial

Highlight

Sibeprenlimab, a humanized monoclonal antibody targeting APRIL, significantly stabilizes kidney function in IgA nephropathy patients over 24 months compared to placebo in a large phase 3 randomized trial. The treatment notably reduced the annualized decline of eGFR and kidney-function deterioration events, with a comparable safety profile to placebo.

Study Background